ERBB2 and large cell neuroendocrine carcinoma: Moreover, 15% of LCNEC tumors showed genetic changes in P13K/AKT/mTOR pathway; it was also observed that LCNEC might have activating mutations in receptor tyrosine kinase genes such as EGFR, KIT, ERBB2 (Umemura et al., 2014, Miyoshi et al., 2017).